 - Human epidermal growth factor 2 HER2 positive and estrogen receptor ER or progesterone receptor PR positive tumors: must be refractory to hormonal therapy e.g. aromatase inhibitor, tamoxifen or fluvestrant and previously treated with at least 2 regimens containing at least two anti-HER2 agents e.g. trastuzumab and pertuzumab. 